Press release
TissueCypher® Provides Clinically-Impactful Risk Stratification in Patients with Barrett’s Esophagus
The TissueCypher Barrett’s Esophagus test can identify patients at a higher or lower risk of developing esophageal cancer than indicated by pathologic
About this update from Castle Biosciences, Inc.
[{"type":"text","content":"\nThe TissueCypher Barrett’s Esophagus test can identify patients at a higher or lower risk of developing esophageal cancer than indicated by pathologic diagnoses and clinical risk factors to guide escalated or de-escalated patient management\n\n\nData to be highlighted at the 19th ISDE World Congress for Esophageal Diseases\n\n\n FRIENDSWOOD, Texas--(BUSINESS WIRE)--\nCastle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will share new data demonstrating the risk stratification performance of its TissueCypher® test in an oral presentation during the Presidential Plenary Session of the 19th ISDE World Congress for Esophageal Diseases, being held Sept. 8-10 in Toronto, Canada.\n\n\n“Current clinical practice guidelines recommend intervention strategies such as close surveillance and endoscopic eradication therapy for Barrett’s patients with low-grade dysplasia due to their increased risk of developing esophageal adenocarcinoma,” said David L. Diehl, M.D., director of the advanced endoscopy fellowship at Geisinger Medical Center and clinical professor of medicine and pathology at the Geisinger Commonwealth School of Medicine. “Based on the data in this study, it is reasonable to conclude that Barrett’s patients with intermediate or high-risk TissueCypher results, regardless of their pathologic diagnosis or clinical risk factors, may benefit from similar, escalated treatment to detect progression early when it is most treatable.”\n\n\nDetails regarding Castle’s presentation are as follows:\n\n\nPPL01.2 The Tissue Systems Pathology-9 Test Provides Clinically-Impactful Risk Stratification in Patients with Barrett’s Esophagus: Clinical Experience in a Multicenter Cohort\nPresenting Author: Michael Yodice, M.D., Department of Gastroenterology and Hepatology at Geisinger Medical Center\nPaper #: 303\nSession: Presidential Plenary Session\nDate & Time: Saturday, Sept. 9, from 9:15-10:30 a.m. Eastern time\nLocation: Osgoode Ballroom East\n\n\nIn the study, TissueCypher test results ordered by 776 physicians from January 2022 to March 2023 for 4,073 patients with Barrett’s esophagus (BE) were analyzed. Most patients were male (61.8%), under surveillance in a community-based practice (94.9%) and had a diagnosis of non-dysplastic Barrett’s esophagus (NDBE) (95.1%), which is repr...